Mavrilimumab - Kiniksa Pharmaceuticals

Drug Profile

Mavrilimumab - Kiniksa Pharmaceuticals

Alternative Names: Anti-GM-CSFR monoclonal antibody - MedImmune; CAM-3001; KPL-301

Latest Information Update: 10 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zenyth Therapeutics
  • Developer Kiniksa Pharmaceuticals; MedImmune
  • Class Antirheumatics; Monoclonal antibodies; Vascular disorder therapies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Giant cell arteritis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 06 Aug 2018 Kiniksa Pharmaceuticals announces intention to submit IND and CTA for a phase II trial for Giant cell arthritis in 2H 2018 (Kiniksa Pharmaceuticals pipeline, May 2018)
  • 06 Aug 2018 Kiniksa Pharmaceuticals plans a pre-investigational new drug application meeting with US FDA for Giant cell arteritis
  • 09 Jul 2018 Phase-II clinical trials in Giant cell arteritis (In adults, In the elderly) in Estonia (SC) (EudraCT2018-001003-36; KPL-301-C001 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top